Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Beacon Biosignals
Deal Size : Undisclosed
Deal Type : Collaboration
Gate Neurosciences Partners with Beacon Biosignals on EEG Biomarkers for Depression
Details : Beacon's Dreem™ 3S headband will be used to analyze EEG and sleep in depressed patients during Phase 2 trials of zelquistinel, an NMDA receptor modulator.
Brand Name : GATE-251
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 24, 2024
Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Beacon Biosignals
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?